Search
Atara Biotherapeutics Inc
ATRAAdd to Watchlist
11.650USD
+0.280+2.46%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
104.97MMarket Cap
LossP/E TTM
More Details of Atara Biotherapeutics Inc Company
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
Atara Biotherapeutics Inc Info
Ticker SymbolATRA
Company nameAtara Biotherapeutics Inc
IPO dateOct 16, 2014
CEONguyen (Anhco)
Number of employees153
Security typeOrdinary Share
Fiscal year-endOct 16
Address1280 Rancho Conejo Blvd
CityTHOUSAND OAKS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code91320
Phone18056234211
Websitehttps://www.atarabio.com/
Ticker SymbolATRA
IPO dateOct 16, 2014
CEONguyen (Anhco)
Company Executives of Atara Biotherapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. William K. Heiden
Mr. William K. Heiden
Independent Director
Independent Director
26.36K
+45.52%
Ms. Carol G. Gallagher, Pharm.D.
Ms. Carol G. Gallagher, Pharm.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Mr. Anhco (Cokey) Nguyen, Ph.D.
Mr. Anhco (Cokey) Nguyen, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Amber Daugherty
Mr. Amber Daugherty
Senior Director, Strategy and Operations
Senior Director, Strategy and Operations
--
--
Mr. James Huang
Mr. James Huang
Independent Director
Independent Director
--
--
Mr. Nachi Subramanian
Mr. Nachi Subramanian
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. William K. Heiden
Mr. William K. Heiden
Independent Director
Independent Director
26.36K
+45.52%
Ms. Carol G. Gallagher, Pharm.D.
Ms. Carol G. Gallagher, Pharm.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Mr. Anhco (Cokey) Nguyen, Ph.D.
Mr. Anhco (Cokey) Nguyen, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Amber Daugherty
Mr. Amber Daugherty
Senior Director, Strategy and Operations
Senior Director, Strategy and Operations
--
--
FAQs
Who are the top five shareholders of Atara Biotherapeutics Inc?
The top five shareholders of Atara Biotherapeutics Inc are: Mr. William K. Heiden
How many institutions hold shares of Atara Biotherapeutics Inc (ATRA)?
As of 2026Q1, 156 institutions hold shares of Atara Biotherapeutics Inc, with a combined market value of approximately 3.70M, accounting for 43.48% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -645280.00.